Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Depreciation & Amortization (CF) (2023 - 2025)

Bioregenx's Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $37945.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $37945.0 for Q4 2025, down 93.39% from a year ago — trailing twelve months through Dec 2025 was $100076.0 (down 95.49% YoY), and the annual figure for FY2025 was $75075.0, down 96.62%.
  • Depreciation & Amortization (CF) for Q4 2025 was $37945.0 at Bioregenx, up from $12377.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $574466.0 in Q3 2024 to a low of $1193.0 in Q2 2023.
  • The 3-year median for Depreciation & Amortization (CF) is $24877.0 (2025), against an average of $193670.2.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 48053.06% in 2024, then crashed 97.85% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1194.0 in 2023, then soared by 48012.73% to $574466.0 in 2024, then tumbled by 93.39% to $37945.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $37945.0, $12377.0, and $37377.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.